Unicycive Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a nine-month net loss of $21.543 million and total assets of $69.933 million.

Key Highlights

  • Nine-month net loss: $21.543 million for the nine months ended September 30, 2026, compared to $11.887 million for the same period in 2025, according to the filing.
  • Third-quarter net loss: $6.997 million for the three months ended September 30, 2026, versus $6.011 million in the prior-year quarter.
  • Cash and cash equivalents: $41.966 million as of September 30, 2026, up from $29.198 million at December 31, 2025.
  • Total assets increased: $69.933 million as of September 30, 2026, compared to $49.135 million at December 31, 2025.
  • Shares outstanding grew: Common shares issued and outstanding rose to 29,110,352 at September 30, 2026, from 22,114,245 at December 31, 2025.
  • Warrant liability declined: The warrant liability decreased to $12.377 million at September 30, 2026, from $16.915 million at December 31, 2025.
  • Accumulated deficit: $149.367 million as of September 30, 2026, compared to $127.825 million at December 31, 2025.

Unicycive Therapeutics Financial Results for the Nine Months Ended September 30, 2026

According to the filing, Unicycive Therapeutics (NASDAQ:UNCY) reported total operating expenses of $27.418 million for the nine months ended September 30, 2026, comprised of $6.642 million in research and development expenses and $20.776 million in general and administrative expenses. This compares to total operating expenses of $22.293 million for the nine months ended September 30, 2025, which included $6.871 million in research and development and $15.422 million in general and administrative expenses.

The filing disclosed that other income for the nine-month period included $1.338 million in interest income and a $4.537 million gain from the change in fair value of the warrant liability, partially offsetting the operating loss of $27.418 million. For the third quarter of 2026 alone, the company reported a $1.341 million gain from the change in fair value of the warrant liability and $503 thousand in interest income, the filing stated. Net loss per share, basic and diluted, was $(0.82) for the nine months ended September 30, 2026, based on weighted-average shares outstanding of 26,381,775.

The company disclosed that it raised capital during the nine months ended September 30, 2026, through multiple common stock issuances. These included 3,123,537 shares issued in Q1 2026 for net proceeds of $19.569 million and 2,155,230 shares issued in Q2 2026 for net proceeds of $14.439 million, as reflected in the stockholders' equity statements. Total stockholders' equity stood at $52.624 million as of September 30, 2026, up from $30.197 million at December 31, 2025. The company reported 29,184,509 shares of common stock issued and outstanding as of November 16, 2026.

What Was Disclosed

Unicycive Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $21.543 million, cash of $41.966 million, total assets of $69.933 million, and an accumulated deficit of $149.367 million, alongside multiple common stock issuances during the period.